Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons

Lisa A Jackson, Manjusha J Gaglani, Harry L Keyserling, John Balser, Nancy Bouveret, Louis Fries, John J Treanor, Lisa A Jackson, Manjusha J Gaglani, Harry L Keyserling, John Balser, Nancy Bouveret, Louis Fries, John J Treanor

Abstract

Background: Seasonal influenza imposes a substantial personal morbidity and societal cost burden. Vaccination is the major strategy for influenza prevention; however, because antigenically drifted influenza A and B viruses circulate annually, influenza vaccines must be updated to provide protection against the predicted prevalent strains for the next influenza season. The aim of this study was to assess the efficacy, safety, reactogenicity, and immunogenicity of a trivalent inactivated split virion influenza vaccine (TIV) in healthy adults over two influenza seasons in the US.

Methods: The primary endpoint of this double-blind, randomized study was the average efficacy of TIV versus placebo for the prevention of vaccine-matched, culture-confirmed influenza (VMCCI) across the 2005-2006 and 2006-2007 influenza seasons. Secondary endpoints included the prevention of laboratory-confirmed (defined by culture and/or serology) influenza, as well as safety, reactogenicity, immunogenicity, and consistency between three consecutive vaccine lots. Participants were assessed actively during both influenza seasons, and nasopharyngeal swabs were collected for viral culture from individuals with influenza-like illness. Blood specimens were obtained for serology one month after vaccination and at the end of each influenza season's surveillance period.

Results: Although the point estimate for efficacy in the prevention of all laboratory-confirmed influenza was 63.2% (97.5% confidence interval [CI] lower bound of 48.2%), the point estimate for the primary endpoint, efficacy of TIV against VMCCI across both influenza seasons, was 46.3% with a 97.5% CI lower bound of 9.8%. This did not satisfy the pre-specified success criterion of a one-sided 97.5% CI lower bound of >35% for vaccine efficacy. The VMCCI attack rates were very low overall at 0.6% and 1.2% in the TIV and placebo groups, respectively. Apart from a mismatch for influenza B virus lineage in 2005-2006, there was a good match between TIV and the circulating strains. TIV was highly immunogenic, and immune responses were consistent between three different TIV lots. The most common reactogenicity events and spontaneous adverse events were associated with the injection site, and were mild in severity.

Conclusions: Despite a good immune response, and an average efficacy over two influenza seasons against laboratory-confirmed influenza of 63.2%, the pre-specified target (lower one-sided 97.5% confidence bound for efficacy > 35%) for the primary efficacy endpoint, the prevention of VMCCI, was not met. However, the results should be interpreted with caution in view of the very low attack rates we observed at the study sites in the 2005-2006 and 2006-2007, which corresponded to relatively mild influenza seasons in the US. Overall, the results showed that TIV has an acceptable safety profile and offered clinical benefit that exceeded risk.

Trial registration: NCT00216242.

Figures

Figure 1
Figure 1
Enrollment and Inclusion in Analysis Sets over Two Seasons.

References

    1. Schanzer DL, Langley JM, Tam TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J. 2006;25(9):795–800. doi: 10.1097/01.inf.0000232632.86800.8c.
    1. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333–1340. doi: 10.1001/jama.292.11.1333.
    1. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179–186. doi: 10.1001/jama.289.2.179.
    1. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086–5096. doi: 10.1016/j.vaccine.2007.03.046.
    1. Thompson WW, Comanor L, Shay DK. Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis. 2006;194(Suppl 2):S82–91. doi: 10.1086/507558.
    1. Li S, Leader S. Economic burden and absenteeism from influenza-like illness in healthy households with children (5-17 years) in the US. Respir Med. 2007;101(6):1244–1250. doi: 10.1016/j.rmed.2006.10.022.
    1. Nichol KL, D'Heilly SJ, Greenberg ME, Ehlinger E. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50-64 years. Clin Infect Dis. 2009;48(3):292–298. doi: 10.1086/595842.
    1. World Health Organization. WHO Global Influenza Surveillance Network. [Accessed March 2010]
    1. World Health Organization. Recommendations for influenza vaccines. [Accessed March 2010]
    1. Wright P, Webster R. In: Fields virology. 4. Knipe DM, Howley PM, Griffin DE, et al, editor. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. Orthomyxoviruses; pp. 1534–1579.
    1. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, Glezen WP, Wittes J. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999;282(2):137–144. doi: 10.1001/jama.282.2.137.
    1. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, Monto AS. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006;355(24):2513–2522. doi: 10.1056/NEJMoa061850.
    1. Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, Newton DW, Campbell SA, Boulton ML, Monto AS. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis. 2008;198(3):312–317. doi: 10.1086/589885.
    1. Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007. p. CD001269.
    1. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis. 1994;169(1):68–76.
    1. Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, Wittes J, Bryant M. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine. 1999;18(9-10):899–906. doi: 10.1016/S0264-410X(99)00334-5.
    1. US Food and Drug Administration. Product Approval Information - Licensing Action. 2006. Accessed March 2010.
    1. Centers for Disease Control. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Accessed March 2010.
    1. Redlberger M, Aberle S, Heinz F, Popow-Kraupp T. Dynamics of antigenic and genetic changes in the hemagglutinins of influenza A/H3N2 viruses in three consecutive seasons (2002/2003 to 2004/2005) in Austria. Vaccine. 2007;25:6061–6069. doi: 10.1016/j.vaccine.2007.05.045.
    1. Kendal A, Pereira M, Skehel J. In: Hemagglutination inhibition. Concepts and procedures for laboratory-based influenza surveillance. Kendal AP, Pereira MS, Skehel JJ, editor. Atlanta: Centers for Disease Control and Prevention and Pan-American Health Organization; 1982. pp. B17–35.
    1. Centers for Disease Control. Flu activity and surveillance. Accessed March 2010.
    1. Wiens B, Iglewicz B. Design and analysis of three treatment equivalence trials. Control Clin Trials. 2001;21:127–137. doi: 10.1016/S0197-2456(99)00052-5.
    1. Centers for Disease Control. 2005-2006 influenza season summary. Accessed March 2010.
    1. Centers for Disease Control. 2006-2007 influenza season summary. [Accessed March 2010]
    1. Beran J, Wertzova V, Honegr K, Kaliskova E, Havlickova M, Havlik J, Jirincova H, Van Belle P, Jain V, Innis B. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis. 2009;9:2. doi: 10.1186/1471-2334-9-2.
    1. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2008;16(2):CD004879.
    1. Langley J, Faughnan M. Prevention of influenza in the general population. CMAJ. 2004;171:1213–1222.
    1. Rudenko LG, Arden NH, Grigorieva E, Naychin A, Rekstin A, Klimov AI, Donina S, Desheva J, Holman RC, DeGuzman A. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine. 2000;19(2-3):308–318.
    1. Zangwill KM, Belshe RB. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J. 2004;23(3):189–197. doi: 10.1097/01.inf.0000116292.46143.d6.
    1. Langley J, Faughnan M. Prevention of influenza in the general population. CMAJ. 2004;171:1213–1222.
    1. Hoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Kearney DH, Colborn DK, Kurs-Lasky M, Haralam MA, Byers CJ. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA. 2003;290(12):1608–1616. doi: 10.1001/jama.290.12.1608.
    1. Zambon M, Hays J, Webster A, Newman R, Keene O. Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch Intern Med. 2001;161(17):2116–2122. doi: 10.1001/archinte.161.17.2116.
    1. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacuzio D, Piedra P, Treanor J. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136(2):168–175. doi: 10.1016/S0022-3476(00)70097-7.
    1. Nichol KL. Heterogeneity of influenza case definitions and implications for interpreting and comparing study results. Vaccine. 2006;24(44-46):6726–6728. doi: 10.1016/j.vaccine.2006.05.064.
    1. Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, Klimov A, Keitel WA, Nichol KL, Carr WW. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008;168(22):2405–2414. doi: 10.1001/archinternmed.2008.513.
    1. US Food and Drug Administration. Guidance for Industry. Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. Accessed March 2010.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj